The promise of the human genome project is beginning to be fulfilled. Rapid whole-genome sequencing is now a reality. At the same time, ever more powerful techniques have been developed which have enabled tiny amounts of DNA to be detected from a sample; and we have editing techniques which allow us to precisely target and modify specific genes.
These exciting development are underpinned by core platform technologies. At Mewburn Ellis, we have considerable experience of providing IP protection for core platforms in molecular biology, as well as their innovative applications in research, agriculture and medicine. Many of our experienced patent attorneys have laboratory experience in this area and are supported by talented new recruits with up-to-date practical expertise.
Our work encompasses a wide range of genetic engineering, synthetic biology and analytic techniques. We have recently assisted the University of California, Berkley in the UK in obtaining European patents for CRISPR-Cas9 technology. We also have a long history of working with next-generation sequencing companies, including those developing approaches to single molecule and deep sequencing.
Bioinformatics is becoming critically important in handling and interpreting the vast amount of data that can be generated from molecular biology. We offer a cross-disciplinary group with both IP and scientific expertise in this area. We also have a close working relationship with the specialist group of bioinformatics Examiners at the EPO. We can advise on how to write and prosecute patents with the best chances of success, taking into account the often complex requirements both in Europe and worldwide.
Read more on our Bioinformatics spotlight page.
